PMID- 32446306
OWN - NLM
STAT- MEDLINE
DCOM- 20210324
LR  - 20210324
IS  - 1476-511X (Electronic)
IS  - 1476-511X (Linking)
VI  - 19
IP  - 1
DP  - 2020 May 23
TI  - Fenofibrate decreased microalbuminuria in the type 2 diabetes patients with 
      hypertriglyceridemia.
PG  - 103
LID - 10.1186/s12944-020-01254-2 [doi]
LID - 103
AB  - BACKGROUND: This study was to research the efficacy of fenofibrate in the 
      treatment of microalbuminuria in the patients with type 2 diabetes mellitus 
      (T2DM) and hypertriglyceridemia. METHODS: Type 2 diabetic patients (56) with 
      microalbuminuria and hypertriglyceridemia aged 30 to 75 were randomly divided 
      into the fenofibrate treatment group(n = 28) and the control group (n = 28) for 
      180 days. Urinary microalbumin /creatinine ratio (UACR) and other metabolic 
      parameters were compared at baseline, during treatment and after treatment. 
      RESULTS: After 180 days, the reduction of level of fasting blood glucose (FBG) 
      and glycosylated hemoglobin (HbA1c) between two groups showed no difference. In 
      the treatment group, uric acid (UA) (296.42 +/- 56.41 vs 372.46 +/- 72.78), 
      triglyceride (TG) [1.51(1.17, 2.06) vs 3.04(2.21, 3.29)], and UACR [36.45 
      (15.78,102.41) vs 129.00 (53.00, 226.25)] were significantly decreased compared 
      with the baseline. The high-density lipoprotein cholesterol (HDL-C) levels were 
      significantly increased (1.22 +/- 0.26 vs 1.09 +/- 0.24) compared with the baseline. 
      The decrease in UACR [- 44.05(- 179.47, - 12.16) vs - 8.15(- 59.69, 41.94)]in 
      treatment group was significantly higher compared with the control group. The 
      decrease in UACR was positively associated with the decreases in TG (r = 0.447, 
      P = 0.042) and UA (r = 0.478, P = 0.024) after fenofibrate treatment. CONCLUSION: 
      In the patients with hypertriglyceridemia and type 2 diabetes mellitus, 
      fenofibrate can improve microalbuminuria and do not increase the deterioration of 
      glomerular filtration rate. TRIAL REGISTRATION: ClinicalTrials.gov identifier: 
      NCT02314533, 2014.12.9.
FAU - Sun, Xiaomeng
AU  - Sun X
AD  - Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical 
      University, 8 Gongren Tiyuchang Nanlu, Chaoyang District, Beijing, 100020, P. R. 
      China.
FAU - Liu, Jia
AU  - Liu J
AD  - Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical 
      University, 8 Gongren Tiyuchang Nanlu, Chaoyang District, Beijing, 100020, P. R. 
      China.
FAU - Wang, Guang
AU  - Wang G
AD  - Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical 
      University, 8 Gongren Tiyuchang Nanlu, Chaoyang District, Beijing, 100020, P. R. 
      China. drwg6688@126.com.
LA  - eng
SI  - ClinicalTrials.gov/NCT02314533
GR  - 81770792/National Natural Science Foundation of China/
GR  - 81600657/National Natural Science Foundation of China/
GR  - 2018-4-2034/Capital Funds for Health Improvement and Research/
GR  - Z161100000516069/Capital Clinical Research Foundation of Beijing Municipal 
      Commission of Science and Technology/
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20200523
PL  - England
TA  - Lipids Health Dis
JT  - Lipids in health and disease
JID - 101147696
RN  - 0 (Hypolipidemic Agents)
RN  - 0 (Triglycerides)
RN  - 268B43MJ25 (Uric Acid)
RN  - U202363UOS (Fenofibrate)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Albuminuria/*drug therapy/etiology
MH  - Diabetes Mellitus, Type 2/*complications
MH  - Diabetic Nephropathies/*drug therapy
MH  - Female
MH  - Fenofibrate/pharmacology/*therapeutic use
MH  - Glomerular Filtration Rate
MH  - Humans
MH  - Hypertriglyceridemia/complications/*drug therapy
MH  - Hypolipidemic Agents/pharmacology/therapeutic use
MH  - Kidney
MH  - Male
MH  - Middle Aged
MH  - Triglycerides/blood
MH  - Uric Acid
PMC - PMC7245839
OTO - NOTNLM
OT  - Fenofibrate
OT  - Hypertriglyceridemia
OT  - Type 2 diabetes mellitus
OT  - Urinary albumin/creatinine ratio
COIS- The authors declare that they have no competing interests.
EDAT- 2020/05/25 06:00
MHDA- 2021/03/25 06:00
PMCR- 2020/05/23
CRDT- 2020/05/25 06:00
PHST- 2019/12/28 00:00 [received]
PHST- 2020/03/31 00:00 [accepted]
PHST- 2020/05/25 06:00 [entrez]
PHST- 2020/05/25 06:00 [pubmed]
PHST- 2021/03/25 06:00 [medline]
PHST- 2020/05/23 00:00 [pmc-release]
AID - 10.1186/s12944-020-01254-2 [pii]
AID - 1254 [pii]
AID - 10.1186/s12944-020-01254-2 [doi]
PST - epublish
SO  - Lipids Health Dis. 2020 May 23;19(1):103. doi: 10.1186/s12944-020-01254-2.